Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Published on Mar 11, 2017in The Lancet79.323
· DOI :10.1016/S0140-6736(16)32409-6
John P. Neoptolemos127
Estimated H-index: 127
(University of Liverpool),
Daniel H. Palmer46
Estimated H-index: 46
(University of Liverpool)
+ 31 AuthorsJonathan Wadsley26
Estimated H-index: 26
(Weston Park Hospital)
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. Methods We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1:1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m 2 gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m 2 oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. Findings Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28·0 months (95% CI 23·5–31·5) compared with 25·5 months (22·7–27·9) in the gemcitabine group (hazard ratio 0·82 [95% CI 0·68–0·98], p=0·032). 608 grade 3–4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3–4 adverse events in 196 of 366 patients in the gemcitabine group. Interpretation The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma. Funding Cancer Research UK.
📖 Papers frequently viewed together
6 Authors (Lola Rahib, ..., Lynn M. Matrisian)
#1Caterina VivaldiH-Index: 16
#2Chiara CaparelloH-Index: 14
Last. Enrico VasileH-Index: 28
view all 9 authors...
FOLFIRINOX is a standard first-line treatment for advanced pancreatic cancer (aPC). The Gruppo Oncologico Nord Ovest (GONO) FOLFOXIRI regimen demonstrated efficacy in metastatic colorectal cancer. We aimed to evaluate activity and tolerability of FOLFOXIRI regimen in patients with aPC and to explore putative prognostic factors. One hundred thirty-seven consecutive aPC patients were treated with FOLFOXIRI in our institution between 2008 and 2014. Clinical, laboratory and pathological data were co...
#1Katsuhiko UesakaH-Index: 47
#2Narikazu BokuH-Index: 70
Last. Yasuo Ohashi (Chu-Dai: Chuo University)H-Index: 89
view all 20 authors...
Summary Background Although adjuvant chemotherapy with gemcitabine is standard care for resected pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We aimed to investigate the non-inferiority of S-1 to gemcitabine as adjuvant chemotherapy for pancreatic cancer in terms of overall survival. Methods We did a randomised, open-label, multicentre, non-inferiority phase 3 trial undertaken at 33 hospitals in Japan. Patients who had histologically proven invasive ducta...
#1Michela CapelloH-Index: 21
#2Minhee Lee (Fred Hutchinson Cancer Research Center)H-Index: 2
Last. Samir M. HanashH-Index: 94
view all 11 authors...
Abstract Serine hydrolases (SHs) are among the largest classes of enzymes in humans and play crucial role in many pathophysiological processes of cancer. We have undertaken a comprehensive proteomic analysis to assess the differential expression and cellular localization of SHs, which uncovered distinctive expression of Carboxylesterase 2 (CES2), the most efficient carboxyl esterase in activating the prodrug irinotecan into SN-38, in pancreatic ductal adenocarcinoma (PDAC). We therefore assessed...
#1Marianne Sinn (Charité)H-Index: 20
#2Torsten Liersch (GAU: University of Göttingen)H-Index: 47
Last. Hanno Riess (Charité)H-Index: 42
view all 20 authors...
4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...
#1Juan W Valle (University of Manchester)H-Index: 61
#2Daniel H. Palmer (NIHR: National Institute for Health Research)H-Index: 46
Last. Markus W. Büchler (Heidelberg University)H-Index: 177
view all 28 authors...
Purpose Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown. Patients and Methods Patients with pancreatic ductal adenocarcinoma treated within the international, phase III, European Study Group for Pancreatic Cancer–3 (version 2) study were included if they had been randomly assigned to chemotherapy. Overall survival analysis was performed on an intention-to-treat basis, retain...
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. Methods Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3) were stained with the 10D7G2 anti-hENT1 antibody. Patients were classified as having high hENT1 expression if the mean H score for their cores was above the overall median H score (48). High and low h...
#1Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 88
#2Thomas J. ErvinH-Index: 29
Last. Abstr ActH-Index: 45
view all 23 authors...
BACKGROUND In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performan...
#1Helmut Oettle (Charité)H-Index: 19
#2Peter Neuhaus (Charité)H-Index: 107
Last. Hanno Riess (Charité)H-Index: 42
view all 13 authors...
had relapsed and 316 patients (89.3% [95% CI, 85.6%-92.1%]) had died. The median follow-up time was 136 months. The median disease-free survival was 13.4 (95% CI, 11.6-15.3) months in the treatment group compared with 6.7 (95% CI, 6.0-7.5) months in the observation group (hazard ratio, 0.55 [95% CI, 0.44-0.69]; P < .001). Patients randomized to adjuvant gemcitabine treatment had prolonged overall survival compared with those randomized to observation alone (hazard ratio, 0.76 [95% CI, 0.61-0.95]...
#1Wei-Chih Liao (NTU: National Taiwan University)H-Index: 24
#2Kuo-Liong Chien (NTU: National Taiwan University)H-Index: 65
Last. Yu-Kang Tu (NTU: National Taiwan University)H-Index: 55
view all 7 authors...
Summary Background Major adjuvant treatments for pancreatic adenocarcinoma include fluorouracil, gemcitabine, chemoradiation, and chemoradiation plus fluorouracil or gemcitabine. Since the optimum regimen remains inconclusive, we aimed to compare these treatments in terms of overall survival after tumour resection and in terms of grade 3–4 toxic effects with a systematic review and random-effects Bayesian network meta-analysis. Methods We searched PubMed, trial registries, and related reviews an...
#1John P. Neoptolemos (University of Liverpool)H-Index: 127
#2Trevor Cox (University of Liverpool)H-Index: 28
Cited By886
#1Yiyin Zhang (Fudan University)H-Index: 12
#2Jin XuH-Index: 41
Last. Si ShiH-Index: 25
view all 4 authors...
#1Karen AughtonH-Index: 4
#2Nils O. ElanderH-Index: 6
Last. Juan W ValleH-Index: 61
view all 26 authors...
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside of the cancer cell, will deaminate gemcitabine, altering transporter affinity. ESPAC-3(v2) was a pancreatic cancer trial comparing adjuvant gemcitabine and 5-FU. Tissue microarray sections underwent in situ hybridization and immunohistochemistry. Analysis o...
#1Shimpei Maeda (UCLA: University of California, Los Angeles)H-Index: 8
#2Michael A. Mederos (UCLA: University of California, Los Angeles)H-Index: 2
Last. Timothy R. Donahue (UCLA: University of California, Los Angeles)H-Index: 37
view all 21 authors...
Abstract null null Background null Pathological treatment effect of resected pancreatic adenocarcinoma after neoadjuvant therapy has prognostic implications. The impact for patients who received chemotherapy alone or chemoradiotherapy is not well defined. null null null Methods null Patients with localized pancreatic adenocarcinoma who had pancreatectomy after neoadjuvant therapy at 3 centers from 2011 to 2017 were retrospectively analyzed. The chemotherapy and chemoradiotherapy groups were eval...
#1Anna Nießen (Heidelberg University)H-Index: 3
#2Thilo Hackert (Heidelberg University)H-Index: 57
BACKGROUND The d evelopment of surgical techniques and specialization and specifically complication management in pancreatic surgery have improved surgical outcomes as well as oncological results in pancreatic surgery in recent decades. Historical morbidity and especially mortality rates of up to 80% have decreased to below 5% today. This review summarizes the current state of the art in pancreatic cancer surgery. METHODS The present literature and clinical experience are summarized to give an o...
#1Monish Karunakaran (Medanta)H-Index: 2
#2Savio G. Barreto (Flinders University)H-Index: 22
Two areas that remain the focus of improvement in pancreatic cancer include high post-operative morbidity and inability to uniformly translate surgical success into long-term survival. This narrative review addresses specific aspects of pancreatic cancer surgery, including neoadjuvant therapy, vascular resections, extended pancreatectomy, extent of lymphadenectomy and current status of minimally invasive surgery. R0 resection confers longer disease-free survival and overall survival. Vascular an...
#1Zhou Xu (Heidelberg University)
#2Kai Hu (Heidelberg University)H-Index: 1
Last. Jingyu An (Heidelberg University)
view all 15 authors...
Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the seventh commonest cause of cancer death in the world, with the highest mortality rates in Europe and North America. In the past 30 years there has been some progress in 5-year survival (rates increasing from 2.5% to 10%, but this is still extremely poor compared to all other common cancer types. Targeted therapies for advanced pancreatic cancer based on actionable mutations have been disappointing, with only...
#1Mike Nguyen (Monash University)
#2Eva Segelov (Monash University)H-Index: 25
Last. Amitesh Roy (Flinders University)H-Index: 13
view all 17 authors...
Introduction null Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localised and advanced pancreatic cancer and offers an expert opinion on current best practice. null Areas covered null For patients with localised disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resecta...
Introducao: As neoplasias pancreaticas sao tumores altamente agressivos e apresentam a deteccao precoce e o tratamento cirurgico como as unicas opcoes curativas. Dessa forma, trata-se de um tumor com alta recorrencia e baixa sobrevida. Objetivos: O objetivo desse estudo e revisar sobre o manejo do câncer de pâncreas, visto que se trata da neoplasia mais letal do trato gastrointestinal. Metodos: Os bancos de dados Pubmed, Diretrizes e UpToDate foram pesquisados eletronicamente utilizando os descr...
#1Nicola de Liguori Carino (Manchester Royal Infirmary)H-Index: 8
#2Minas Baltatzis (Manchester Royal Infirmary)H-Index: 7
Last. Derek A. O'Reilly (Manchester Royal Infirmary)H-Index: 25
view all 10 authors...
Abstract null null Introduction null The aim was to perform a propensity-matched comparison of patients with pancreatic cancer undergoing surgery, with and without biliary stenting; and an intention to treat analysis of long-term survival between the two groups. null null null Methods null This was an observational study of a cohort of consecutive patients presenting with obstructive jaundice and undergoing pancreatoduodenectomy for pancreatic and periampullary malignancies between November 2015...
#1Dominique Lisa Birrer (UZH: University of Zurich)H-Index: 1
#2Henriette Golcher (FAU: University of Erlangen-Nuremberg)H-Index: 9
Last. Robert Grützmann (FAU: University of Erlangen-Nuremberg)H-Index: 64
view all 27 authors...
OBJECTIVE The aim of this study was to pool data from randomized controlled trials (RCT) limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a neoadjuvant therapy impacts on disease-free survival (DFS) and surgical outcome. SUMMARY BACKGROUND DATA Few underpowered studies have suggested benefits from neoadjuvant chemo (± radiation) for strictly resectable PDAC without offering conclusive recommendations. METHODS Three RCTs were identified comparing neoadjuvant chem...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.